Understanding allergic rhinitis

Understanding allergic rhinitis

Did you know that allergic rhinitis is an underestimated and untreated condition?

Allergic rhinitis is inflammation of the membranes lining the nose, which occurs when they become sensitised to allergens.1

It is a very common condition, estimated to affect around one in every five people in the UK. A person with allergic rhinitis typically presents with sneezing, redness in the eyes, itching of the nose and eyes, and nasal discharge and/or blockage.1

Patients can have allergic rhinitis symptoms all year round which affects their daily activities.2

dymista

Allergic rhinitis is an underestimated and undertreated condition

  • Slide
  • Slide
  • Slide
  • Slide
  • Slide
Click to download full slide deck
  • Allergi
    Allergic Rhinitis
  • Impact
    Impact of Rhinitis
  • Impact
    Onset
  • Impact
    Treatment
  • Guidelines
    Guidelines
  • Clinical Papers
    Clinical Papers

References

  1. Pitman R. Paracha N et al. Episode pattern and healthcare utilisation in patients with season allergic rhinitis. Poster presented at the 31st Congress of the European Academy of Allergy and Clinical Immunology (EAACI)2012.
  2. Walker S. Khan-Wasti S, et al. Seasonal allergic rhinitis is associated with a detrimental effect on examination Performance in Uniteded Kingdom teenagers: Case-control study. Journal of Allergy and Clinical Immunology 2007; 120(2):381-387

Want to expand your knowledge?

Register to ViatrisConnect and subscribe to our Allergy newsletters to continue reading.

Mylan Connects

Viatris Connect is an online platform for healthcare professionals. Register today and enjoy this article and a selection of others for free.

REGISTER NOW

Viatris Connect is an online platform for UK health Professionals.

Across the website you will find news, blogs and product information.

Register to Viatris Connect today

Please note that the website contains promotional and non-promotional material including educational content and resources to help you and your patients.

REGISTER NOW

Please continue to report suspected adverse drug reactions and device failures with any medicine or vaccine to the MHRA through the Yellow Card Scheme.

It is easiest and quickest to report adverse drug reactions and device failures online via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Alternatively, you can report via some clinical IT systems (EMIS/SystmOne/Vision/MiDatabank) or by calling the Commission on Human Medicines (CHM) free phone line: 0800-731-6789.
Adverse reactions/events and device failures should also be reported to MAH at e-mail address: pv.uk@viatris.com.

This website is owned and managed by Viatris. For more information visit viatris.co.uk


This site is intended for UK healthcare professionals only. If you're a patient who has been prescribed Dymista® (azelastine hydrochloride/fluticasone propionate), please ​click here.

Dymista® is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.​

Copyright © 2023 Viatris Inc All rights reserved. Dymista® is a registered trademark of Viatris Inc.

Viatris UK Healthcare Limited (company registration number 09189103), an English company with a registered office address at 20 Station Close, Potters Bar, Hertfordshire, EN6 1TL (VAT - 421 623 781)

Mylan Logo